M79, this 'actions speak louder than words approach' has been Silviu's policy from Day 1.The companies MPC technology has seen stunning results in the various clinical trials to date.
Eyal Desheh, recently was quoted as saying “The ones that you can buy one and one and get to two, I know it’s a cliché. But we’re very good at doing that. And I think that these are the kind of deals that we’ll be looking at in the future."
Maybe he was inspired by the Osiris acquisition (lol).
I think Silvius strategy on Osiris is still to play out..as we all know particularly with Japan. Also having 2 MSC P3 trials gives MSB the ammunition to lobby FDA for accelerated approval (I’m sure he will go for both MSC & MPC).
Can you imagine if we get a positive response from the FDA re ‘speed up clearance for the novel therapies”?
Just excited about what will transpire in Qrt 1 CL2014.GLTAH.
fait accompli, page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |